Lars Lannfelt

39.9k total citations · 7 hit papers
312 papers, 20.7k citations indexed

About

Lars Lannfelt is a scholar working on Physiology, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Lars Lannfelt has authored 312 papers receiving a total of 20.7k indexed citations (citations by other indexed papers that have themselves been cited), including 244 papers in Physiology, 148 papers in Molecular Biology and 74 papers in Psychiatry and Mental health. Recurrent topics in Lars Lannfelt's work include Alzheimer's disease research and treatments (238 papers), Dementia and Cognitive Impairment Research (70 papers) and Prion Diseases and Protein Misfolding (41 papers). Lars Lannfelt is often cited by papers focused on Alzheimer's disease research and treatments (238 papers), Dementia and Cognitive Impairment Research (70 papers) and Prion Diseases and Protein Misfolding (41 papers). Lars Lannfelt collaborates with scholars based in Sweden, United States and United Kingdom. Lars Lannfelt's co-authors include Bengt Winblad, Martin Ingelsson, Hans Basun, Karin Axelman, Kaj Blennow, Dag Sehlin, Lena Lilius, Lars Nilsson, Henry Houlden and Lars‐Olof Wahlund and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Lars Lannfelt

308 papers receiving 20.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid

1992 1.1k citations Henry Houlden, Lena Lilius et al. profile →
The Amyloid-β Pathway in Alzheimer’s Disease

2021 1.1k citations Harald Hampel, John Hardy et al. Molecular Psychiatry profile →
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation

2001 943 citations Charlotte Forsell, Lars Lannfelt et al. profile →
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

2008 586 citations Lars Lannfelt, Kaj Blennow et al. profile →
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

2021 580 citations Lars Lannfelt, Jeffrey L. Cummings et al. profile →
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers

2018 391 citations Lars Lannfelt, Martin Ingelsson et al. profile →
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

2022 270 citations Linda Söderberg, Malin Johannesson et al. Neurotherapeutics profile →

Peers

Countries citing papers authored by Lars Lannfelt

Since Specialization

Citations

This map shows the geographic impact of Lars Lannfelt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Lannfelt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Lannfelt more than expected).

Fields of papers citing papers by Lars Lannfelt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Lannfelt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Lannfelt. The network helps show where Lars Lannfelt may publish in the future.

Co-authorship network of co-authors of Lars Lannfelt

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Lannfelt. A scholar is included among the top collaborators of Lars Lannfelt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Lannfelt. Lars Lannfelt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice 2025 ·Nature Aging ·Emelie Andersson, (unknown), Shorena Janelidze, Gemma Salvadó, Eleni Gkanatsiou, Linda Söderberg, Christer Möller, Lars Lannfelt, Junyue Ge, Jörg Hanrieder, Kaj Blennow, Tomas Deierborg, Niklas Mattsson, Henrik Zetterberg, Gunnar K. Gouras, Oskar Hansson	11
2	A light at the end of the tunnel – from mutation identification to a potential treatment for Alzheimer’s disease 2023 ·Upsala Journal of Medical Sciences ·Lars Lannfelt	4
3	Aβ and tau prions feature in the neuropathogenesis of Down syndrome 2022 ·Proceedings of the National Academy of Sciences ·Carlo Condello, Alison M. Maxwell, Erika Castillo, Atsushi Aoyagi, Caroline Graff, Martin Ingelsson, Lars Lannfelt, Thomas D. Bird, C. Dirk Keene, William W. Seeley, Daniel P. Perl, Elizabeth Head, Stanley B. Prusiner	17
4	Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease breakdown → 2022 ·Neurotherapeutics ·Linda Söderberg, Malin Johannesson, Patrik Nygren, Hanna Laudon, Fredrik Eriksson, Gunilla Osswald, Christer Möller, Lars Lannfelt	270
5	The Amyloid-beta Pathway in Alzheimer's Disease 2021 ·Molecular Psychiatry ·Harald Hampel, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L. Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L. Masters, Min Cho, Lars Lannfelt, Jeffrey L. Cummings, Andrea Vergallo	2
6	The Amyloid-β Pathway in Alzheimer’s Disease breakdown → 2021 ·Molecular Psychiatry ·Harald Hampel, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L. Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L. Masters, Min Cho, Lars Lannfelt, Jeffrey L. Cummings, Andrea Vergallo	1099
7	Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-β in Brain 2020 ·ACS Chemical Neuroscience ·Stina Syvänen, Xiaotian T. Fang, (unknown), Johanna Rokka, Lars Lannfelt, Dag Erlend Olberg, Jonas Eriksson, Dag Sehlin	38
8	Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes 2019 ·Neurobiology of Aging ·Ove Almkvist, Elena Rodriguez‐Vieitez, Steinunn Þórðardóttir, Agneta Nordberg, Matti Viitanen, Lars Lannfelt, Caroline Graff	7
9	Aβ and tau prion-like activities decline with longevity in the Alzheimer’s disease human brain 2019 ·Science Translational Medicine ·Atsushi Aoyagi, Carlo Condello, Jan Stöhr, (unknown), (unknown), (unknown), Amanda L. Woerman, Glenda M. Halliday, Sjoerd G. van Duinen, Martin Ingelsson, Lars Lannfelt, Caroline Graff, Thomas D. Bird, C. Dirk Keene, William W. Seeley, William F. DeGrado, Stanley B. Prusiner	95
10	Longitudinal changes in the frequency of mosaic chromosome Y loss in peripheral blood cells of aging men varies profoundly between individuals 2019 ·European Journal of Human Genetics ·Marcus Danielsson, Jonatan Halvardson, Hanna Davies, Behrooz Torabi Moghadam, Jonas Mattisson, Edyta Rychlicka-Buniowska, Janusz Jaszczyński, (unknown), Lars Lannfelt, Vilmantas Giedraitis, Martin Ingelsson, Jan P. Dumanski, Lars A. Forsberg	46
11	Improved Differential Diagnosis of Alzheimer’s Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers 2019 ·Journal of Alzheimer s Disease ·Payam Emami Khoonsari, Ganna Shevchenko, Stephanie Herman, Julia Remnestål, Vilmantas Giedraitis, RoseMarie Brundin, (unknown), Lena Kilander, Henrik Zetterberg, Peter Nilsson, Lars Lannfelt, Martin Ingelsson, Kim Kultima	33
12	Amyloid‐ß‐directed immunotherapy for Alzheimer's disease 2014 ·Journal of Internal Medicine ·Lars Lannfelt, Norman Relkin, Eric Siemers	117
13	Apolipoprotein E increases cell association of amyloid-β 40 through heparan sulfate and LRP1 dependent pathways 2014 ·Amyloid ·P.W. O’Callaghan, Fredrik Noborn, Dag Sehlin, Jin‐Ping Li, Lars Lannfelt, Ulf Lindahl, (unknown)	11
14	Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease 2010 ·Journal of Biological Chemistry ·Oliver Wirths, Christian Erck, Henrik Martens, Anja Harmeier, (unknown), Sadim Jawhar, Sathish Kumar, Gerd Multhaup, Jochen Walter, Martin Ingelsson, Malin Degerman-Gunnarsson, Hannu Kalimo, Inge Huitinga, Lars Lannfelt, Thomas A. Bayer	91
15	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses 2010 ·Journal of Alzheimer s Disease ·Noel G. Faux, Craig Ritchie, Adam P. Gunn, Alan Rembach, Andrew Tsatsanis, Justin Bedő, John Harrison, Lars Lannfelt, Kaj Blennow, Henrik Zetterberg, Martin Ingelsson, Colin L. Masters, Rudolph E. Tanzi, Jeffrey L. Cummings, Caroline M. Herd, Ashley I. Bush	321
16	A Polish pedigree with Alzheimer's disease determined by a novel mutation in exon 12 of the presenilin 1 gene: clinical and molecular characterization. 1999 ·PubMed ·Anna Kowalska, Charlotte Forsell, (unknown), (unknown), (unknown), (unknown), M Wender, Lars Lannfelt	13
17	Protein kinase C and amyloid precursor protein processing in skin fibroblasts from sporadic and familial Alzheimer’s disease cases 1999 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Monika Vestling, Ángel Cedazo-Mı́nguez, Abdu Adem, Birgitta Wiehager, Marco Racchi, Lars Lannfelt, Richard F. Cowburn	22
18	Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. 1997 ·Journal of Clinical Investigation ·V. Large, L Hellström, (unknown), Fredrik Lönnqvist, Per Eriksson, Lars Lannfelt, Peter Arner	343
19	APOLIPOPROTEIN-E GENOTYPE AND ALZHEIMERS-DISEASE 1993 ·UCL Discovery (University College London) ·John Hardy, Henry Houlden, John Collinge, (unknown), (unknown), Martin N. Rossor, Lars Lannfelt, Lena Lilius, Bengt Winblad, Richard Crook, Karen Duff	246
20	THE DOPAMINE D3 RECEPTOR AS A KEY TARGET FOR ANTIPSYCHOTICS 1992 ·Clinical Neuropharmacology ·(unknown), Daniel Lévesque, (unknown), Lars Lannfelt, Jorge Díaz, Caroline Pilon, Schwartz Jc	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact